Keywords: Peregrine Pharma, Bavituximab, Cotara, NSCLC, Commerical viability, GlobalData
GlobalData Expert Insight: Fall from grace of Peregrine Pharma
Article | 17 October 2012
Last month, Peregrine Pharmaceuticals (Nasdaq: PPHM) announced the discovery of “major data discrepancies” between reported results and patient ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
